Flower power may bring ray of sunshine to cancer sufferers

Dr. Jonathan Harris, a senior lecturer in Queensland University of Technology's Faculty of Science, and PhD student Joakim Swedberg, both from the University's Institute of Health and Biomedical Innovation, are working on the naturally occurring molecule, and have received over $600,000 worth of grants this year to support their research.

The grants came from Queensland Cancer Research, the Prostate Cancer Foundation, and the National Health and Medical Research Council. “We are interested in this miniprotein as a potential treatment of prostate cancer, in particular for those patients who relapse,” said Dr Harris.

“The best thing to do in those cases is block the disease spreading to other organs, particularly the spine, which is very debilitating; it is not the prostate tumour that kills you, it is when the cancer cells escape from the prostate so we want to prevent that.”

Another QUT researcher, Professor Judith Clements, had previously shown that the action of enzymes called proteases was a key event in tumour spread, and Dr Harris said that the sunflower mini-protein, known as the protease inhibitor, was able to block these enzymes in test tube-based assays.

“However, it also inhibits a whole range of proteases, some of which control important processes in the body, so we have re-engineered the molecule so it should just block the proteases produced in prostate cancer and hence stop tumour spreading, whilst leaving other processes intact,” he said.

The National Health and Medical Research Council grant will allow Dr Harris and his team to perform tests on the re-engineered inhibitor in animals over the next months.

“It feels like we have been covered in a shower of gold at the moment, it is very exciting for us because we are a small team but we have been working very hard on this for a long time,” he said.

“We are extremely happy because now we can carry out trials in mouse-models of prostate cancer and if we have positive results, we could get a pharmaceutical industry partner interested in the work.

“Currently bluebox, QUT’s commercialisation company, is helping us towards that goal.”

“The dream end-product is having a drug which could be produced in sunflower seeds and given as a simple dietary supplement for people with prostate cancer.”

Source: Queensland University of Technology

Related stories:

'Cutting by color': New imaging technique for more precise cancer surgery
Instead of "paint by number," you might call it "cutting by color": Researchers in Massachusetts now report development and early clinical trials of a new imaging system that highlights cancerous tissue in the body so that surgeons can more easily see and remove diseased tissue with less damage to normal tissue near the tumor. Their research will be presented in August at the American Chemical Society national meeting in Philadelphia.
Vitamin D's wild days: Who to test, what to take?
(AP) -- Don't be surprised if your doctor orders a vitamin D test during your next physical. Blood tests to check levels of the so-called sunshine vitamin are on the rise as doctors and patients react to headline-grabbing research that suggests having too little may not only hurt your bones - it might increase your risk of certain cancers or heart disease.
Synthetic Molecules Could Add Spice To Fight Against Cancer
Seeking to improve on nature, scientists used a spice-based compound as a starting point and developed synthetic molecules that, in lab settings, are able to kill cancer cells and stop the cells from spreading. The researchers are combining organic chemistry, computer-aided design and molecular biology techniques in developing and testing pharmaceutical compounds that can fight breast and prostate cancer cells. The synthetic molecules are derived from curcumin, a naturally occurring compound found in the spice turmeric.
Rheb's role in cancer
Two independent papers in the August 15th issue of G&D identify the Rheb GTPase as a novel oncogene and a promising new chemotherapeutic target.
VA patients in Pa. fear prostate treatment error
(AP) -- A Philadelphia veterans hospital says it may have given insufficient radiation treatment to more than 100 prostate-cancer patients.
Prostatectomy improves outcome of some men with prostate cancer over watchful waiting
Men with early prostate cancer who undergo radical prostatectomy have a lower rate of death due to prostate cancer than men who are followed without treatment, known as watchful waiting, according to a randomized controlled trial published in the August 12 online issue of the Journal of the National Cancer Institute. The benefit from the surgery, with respect to prostate cancer death rates, remained constant beyond 10 years, but the overall death rates in the two groups were not statistically different. The applicability of the results to the current generation of prostate cancer patients is unclear, however, because few of the cancers treated in the trial were discovered by PSA (prostate-specific antigen) screening, a practice that is now widespread.
Study finds more PSA screening awareness needed among high-risk groups
In one of the first examinations of PSA screening in younger men, a study published by researchers at Duke Medicine's Prostate Center finds that one-fifth of men under age 50 reported undergoing a prostate specific antigen (PSA) test to detect prostate cancer in the previous year, yet only one in three young black men reported ever having a PSA test in the previous year.
1 in 5 young men has had recent prostate cancer test
A new analysis finds that one in five men in their 40s has had a prostate specific antigen (PSA) test within the previous year and that young black men are more likely than young white men to have undergone the test. The study, published in the September 15, 2008 issue of Cancer, a peer-reviewed journal of the American Cancer Society, provides valuable information as experts discuss possible changes to prostate cancer screening recommendations.

News discussion:

Medicine & Health news